Welcome to this week’s edition of our newly designed BioLines Weekender, featuring the latest news on New Jersey’s innovative biopharma community.
From Eli Lilly and Company‘s FDA approval of LARTRUVO™ in combination with Doxorubicin for soft tissue sarcoma to the Fast Track designation by the FDA for Chromocell‘s drug candidate (in collaboration with Astellas Pharma) CC8464/ASP1807 for the management of neuropathic pain associated with idiopathic small fiber neuropathy, the Garden State’s life sciences ecosystem continues to bring hope to Patients around the globe.
BioNJ is honored to host our first Patient Advocacy Summit on November 4 at Celgene in Summit. Patients, Patient advocacy groups, industry and government will come together for a meaningful day of Education, Engagement and Empowerment. Click here if you are interested in attending.
Taking place on December 8 at Amicus Therapeutics in Cranbury, Beyond Value Frameworks: Defining the Value of Medical Innovation is an interactive workshop designed for individuals responsible for pricing, policy, market access and reimbursement. Attendees will learn how to get ahead of framework decisions, develop partnerships to challenge value assessments, discuss ways to measure patient-centered value and learn about new analytic computational platforms that can demonstrate and calculate drug value. Click here to register.
Back by popular demand is BioNJ’s Second Annual Inspiring Women in STEM Conference on December 2 at Sanofi in Bridgewater. Bringing together professionals of all levels, the full-day program is designed to encourage and support women involved in all aspects of STEM. The agenda includes networking, interactive sessions and a Fireside Chat with Christi Shaw, former U.S. Country Head, President of Novartis Corporation and President of Novartis Pharmaceuticals.
Please visit www.BioNJ.org for more information on these and other upcoming events.